EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access

Harnessing the ion transportome to treat cancer

Alina L Capatina, Jodie R Malcolm, Aamir Ahmed, Jason Bruce iD, Paul J Buchanan, Thomas R Eykyn iD, Elizabeth M Fitzgerald, Amanda J Foust, Tim G Hales iD, Yoshikatsu Hayashi, Stuart G Higgins iD, Alson Huang and 13 more

The Journal of Physiology · 2026

DOI: 10.1113/jp290738 ↗

At a glance

Übersichtsarbeit in The Journal of Physiology, 2026. Written by Alina L Capatina and 24 co-authors. Institution: Jack Birch Cancer Research Unit, York Biomedical Research Institute, Department of Biology, University of York, York, UK. Major MEDLINE topics: Neoplasms, Ion Transport, Ion Channels. 140 references. The full text is freely available in PubMed Central. Funded by: Physiological Society, Wellcome Trust, York Against Cancer.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Despite significant advances in early detection and therapeutic opportunities, cancer remains a critical global health challenge. The greatest barrier to reducing cancer‐associated mortality is the persistent problem of therapeutic resistance and metastasis. Standard treatment approaches, including surgery combined with chemotherapy and radiation, are effective for many patients with localised disease. However, a substantial proportion of patients will experience recurrence and therapy resistance, leading to treatment failure and poor outcomes. This adverse prognosis for patients highlights the critical need to identify new therapeutic targets capable of improving long‐term survival. The ion transportome comprises ion channels, solute transporters and pumps that regulate controlled movement of sodium (Na + ), potassium (K + ), calcium (Ca 2+ ), chloride (Cl − ) and hydrogen (H + ) across cell membranes. Ion transport is central to many cellular processes, including cell growth, volume regulation, proliferation and migration. In many solid tumours, the finely tuned ionic balance becomes dysregulated, with aberrant expression or activity of membrane transport proteins being closely linked to many of the hallmarks of cancer. Ion channel modulation using pharmacological agents designed to treat channelopathies has demonstrated promise in suppressing cancer progression in preclinical models. Thus, targeting ion‐driven vulnerabilities within solid tumours may complement existing therapies to overcome resistance and improve patient outcomes. The dynamic nature of ion transport mechanisms means that addressing critical research questions regarding their suitability as pharmacological targets is challenging, highlighting the need to develop innovative approaches to study these processes in oncology. image

Subjects

MeSH terms (MEDLINE)

NeoplasmsIon TransportIon ChannelsHumansAnimalsAntineoplastic Agents

Author keywords

cancer channelopathiesdrug repurposinghallmarks of cancerion channelsionic tumour microenvironmenttechnical developmenttherapeutic resistance

Substances

Ion ChannelsAntineoplastic Agents

Authors and institutions

  • Jack Birch Cancer Research Unit, York Biomedical Research Institute, Department of Biology, University of York, York, UK.
  • Centre for Cell and Molecular Dynamics, University College London, London, UK.
  • Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • School of Nursing, Psychotherapy and Community Health, Dublin City University, Dublin, Ireland.
  • School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

ORCID profiles: Jason Bruce, Thomas R Eykyn, Tim G Hales, Stuart G Higgins, Antony P Jackson, Frederick Jones, Sarah J Lilley, Karen McCloskey, Sara Moodad, Hugh Robinson, Samantha C Salvage, Serife Yerlikaya, Jonathan Ashmore, Ruth Murrell-Lagnado, William J Brackenbury

Funding

  • Physiological Society
  • Wellcome Trust
  • York Against Cancer
  • Medical Research Council
  • MRC
  • Mauritius Research Council

Cite

APA

Capatina, A. L., Malcolm, J. R., Ahmed, A., Bruce, J., Buchanan, P. J., Eykyn, T. R., Fitzgerald, E. M., Foust, A. J., Hales, T. G., Hayashi, Y., Higgins, S. G., Huang, A., Jackson, A. P., James, A. D., Jones, F., Lilley, S. J., McCloskey, K., Moodad, S., Robinson, H., …, & Brackenbury, W. J. (2026). Harnessing the ion transportome to treat cancer. The Journal of Physiology. https://doi.org/10.1113/jp290738

Vancouver

Capatina AL, Malcolm JR, Ahmed A, Bruce J, Buchanan PJ, Eykyn TR, et al. Harnessing the ion transportome to treat cancer. The Journal of Physiology. 2026. doi:10.1113/jp290738

BibTeX
@article{Capatina2026,
  author = {Capatina, Alina L and Malcolm, Jodie R and Ahmed, Aamir and Bruce, Jason and Buchanan, Paul J and Eykyn, Thomas R and Fitzgerald, Elizabeth M and Foust, Amanda J and Hales, Tim G and Hayashi, Yoshikatsu and Higgins, Stuart G and Huang, Alson and Jackson, Antony P and James, Andrew D and Jones, Frederick and Lilley, Sarah J and McCloskey, Karen and Moodad, Sara and Robinson, Hugh and Salvage, Samantha C and Soyer, Orkun S and Yerlikaya, Serife and Ashmore, Jonathan and Murrell-Lagnado, Ruth and Brackenbury, William J},
  title = {Harnessing the ion transportome to treat cancer},
  journal = {The Journal of Physiology},
  year = {2026},
  doi = {10.1113/jp290738}
}
Start for free →